Atlas Trials

Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

Clinical trial NCT03786081 · TERMINATED

Trial details

NCT number
NCT03786081
Sponsor
Seagen, a wholly owned subsidiary of Pfizer
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Cervical Cancer
Start date
2019-02-27
Primary completion
2026-03-19
Enrollment
214

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.